Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 10/20 | 0.57 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4102977 | 0.79 | PSMB8 (0.62) | PSMB8NOTUMNPSR1 | |
| SCHEMBL1425626 | 0.79 | PSMB8 (0.62) | PSMB8NOTUM | |
| SCHEMBL4119780 | 0.77 | NOTUM (0.49) | PSMB8NOTUM | |
| SCHEMBL12614772 | 0.76 | PSMB8 (0.68) | PSMB8NOTUM | |
| SCHEMBL459541 | 0.73 | PSMB8 (0.68) | PSMB8NOTUM | |
| SCHEMBL18614390 | 0.73 | PSMB8 (0.68) | PSMB8HDAC1HDAC8HDAC6 | |
| SCHEMBL16363828 | 0.73 | PSMB8 (0.68) | PSMB8 | |
| SCHEMBL14755644 | 0.73 | PSMB8 (1.00) | PSMB8NOTUM | |
| SCHEMBL9627131 | 0.73 | PSMB8 (0.68) | PSMB8 | |
| SCHEMBL12811414 | 0.73 | PSMB8 (0.54) | PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4570313-A2 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-06-18 | — | — | EP | disclosed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| EP-3275440-B1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | NAT CT GERIATRICS & GERONTOLOGY (JP) | 2022-05-04 | — | — | EP | disclosed |
| EP-3275440-B1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | NAT CT GERIATRICS & GERONTOLOGY (JP) | 2022-05-04 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20180072708-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) | 2018-03-15 | — | — | US | disclosed |
| EP-3275440-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | National Center for Geriatrics and Gerontology (JP) | 2018-01-31 | — | — | EP | disclosed |
| EP-3275440-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | National Center for Geriatrics and Gerontology (JP) | 2018-01-31 | — | — | EP | disclosed |
| WO-2016153023-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | 国立研究開発法人国立長寿医療研究センター | 2016-09-29 | — | — | WO | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-8492414-B2 | Antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-07-23 | — | — | US | disclosed |
| US-8492414-B2 | Antibacterial agents | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2013-07-23 | — | — | US | disclosed |
| EP-2200991-B1 | ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD (GB) | 2011-03-23 | — | — | EP | disclosed |
| EP-2200991-B1 | ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-20100273837-A1 | ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD. (GB) | 2010-10-28 | — | — | US | disclosed |
| US-20100273837-A1 | ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD. (GB) | 2010-10-28 | — | — | US | disclosed |
| US-20100273837-A1 | ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD. (GB) | 2010-10-28 | — | — | US | disclosed |
| EP-2200991-A1 | ANTIBACTERIAL AGENTS | Biota Europe Ltd (GB) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009037485-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009037485-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | PSMB8 4329/4885NOTUM 1379/4885NPSR1 3939/4885 |
| US-20100273837-A1 | ANTIBACTERIAL AGENTS | SQOR, SCO2, CYCS | PSMB8 2940/4885NOTUM 3465/4885NPSR1 2738/4885 |
| US-20180072708-A1 | NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME | APP, BACE1, PSEN1 | PSMB8 2009/4885NOTUM 558/4885NPSR1 1162/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | PSMB8 4329/4885NOTUM 1379/4885NPSR1 3939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.